Phase 2 Trial of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B
NCT ID: NCT00869778
Last Updated: 2019-10-01
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
360 participants
INTERVENTIONAL
2009-04-30
2013-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Second Stage:Open-label Study of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B
NCT02862106
Therapeutic Hepatitis B Vaccine (Mimogen-based) Joint Entecavir in Treating Chronic Hepatitis B Patients
NCT01326546
A Clinical Study on Therapeutic Double-plasmid Hepatitis B Virus (HBV) DNA Vaccine in Patients With HBeAg-positive Chronic Hepatitis B
NCT01189656
A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B
NCT04180150
A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B
NCT04426968
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Eligible subjects are enrolled and assigned to 3 groups randomly in a 1:1:1 ratio：
1. εPA-44 600μg group：Subcutaneous inject εPA-44 600μg at week 0, 4, 8, 12, 20, 28；Polyene Phosphatidylcholine Capsules will be taken orally beginning in week 28.
2. εPA-44 900μg group：Subcutaneous inject εPA-44 900μg at week 0, 4, 8, 12, 20, 28；Polyene Phosphatidylcholine Capsules will be taken orally beginning in week 28.
3. Placebo control group：Subcutaneous inject empty liposome at week 0, 4, 8, 12, 20, 28；Polyene Phosphatidylcholine Capsules will be taken orally beginning in week 28.
The study cycle consists of screening and enrollment period (week -6-0), treatment period (week 0-28) and follow-up period (week 28-76).
Second stage(76-144 weeks):
In this follow-up stage the trial is open designed, and all the subjects completed the first stage study(0-76 weeks):
1. Subjects with no virological response and no serological response in the first stage , and refuse to continue the this follow-up study, will be provided domestic Adefovir Dipivoxil for one year freely;
2. Subjects with virological response but no serological response/with serological response but no virological response/neither virological nor serological response in the first stage, and be willing to continue the this follow-up study, will be treated by εPA-44 900 μg；
3. Subjects with both virological and serological response, will be followed-up to 144 weeks with no Adefovir Dipivoxil or εPA-44 900 μg treatment.
The definition of response is defined as below:
1. Virological response: HBV DNA\<2.93×10∧3IU/ml at 76 weeks;
2. Serological response: serological conversion of HBeAg at 76 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
εPA-44 900μg
Inject εPA-44 900μg at week 0, 4, 8, 12, 20, 28.
εPA-44
subcutaneously injection of εPA-44 at week 0, 4, 8, 12, 20, 28.
εPA-44 600μg+Placebo 300μg
Inject εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.
εPA-44
subcutaneously injection of εPA-44 at week 0, 4, 8, 12, 20, 28.
Placebo
subcutaneously injection of Placebo at week 0, 4, 8, 12, 20, 28.
Placebo 900μg
Inject Placebo 900μg at week 0, 4, 8, 12, 20, 28.
Placebo
subcutaneously injection of Placebo at week 0, 4, 8, 12, 20, 28.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
εPA-44
subcutaneously injection of εPA-44 at week 0, 4, 8, 12, 20, 28.
Placebo
subcutaneously injection of Placebo at week 0, 4, 8, 12, 20, 28.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Conforms to diagnosis standard of chronic hepatitis B according to"2005 Guideline for Prevention and Treatment of Hepatitis B", (with positive HBsAg for more than 6 months), and HBV-DNA more than 100000 copies/ml;HBeAg (+),HBsAb(-); Alanine aminotransferase（ALT） within 2 to 10 times of ULN (upper limit of normal)
3. HLA-A2 positive
4. Compensatory liver disease having following hematological and biochemical indicators:WBC≥3.5E+9/L; ANC≥1.5E+9/L; PLT≥80E+9/L; Hb≥110g/L; TBil≤1.5ULN; ALB ≥ lower limit of normal value; BUN (Urea)≤upper limit of normal value; Cr≤upper limit of normal value; prothrombin time(PT) elongation≤3 sec; Activated partial thromboplastin time（APTT） within normal value; Fasting blood glucose≤7.0mmol/L
5. TSH within normal value
6. AFP ≤20ng/ml
7. Uses effective contraception for subject with child-bearing potential (including females and female partners of males)
8. Understands and signs ICF approved by EC
9. Willing to comply with the study procedures and complete the study
Exclusion Criteria
2. Antibody of CMV IgM, EBV IgM or HIV is positive
3. Antinuclear antibody titer\>1:160
4. Hepatocarcinoma, suspected hepatocarcinoma or hepatic cirrhosis
5. Has any of the following illnesses or has a severe disease inappropriate for participation in the study based on the investigator's judgment, such as: Cardiovascular system: instable or significant cardiovascular illness such as angina pectoris, heart attack of myocardial infarction, congestive heart failure, severe hypertension, significant arrhythmia or abnormal ECG etc.; Respiratory system: bronchiectasis, bronchial asthma, chronic obstructive pulmonary disease, respiratory failure, etc.; Endocrine, metabolism diseases: diabetes mellitus, uncontrolled thyroid diseases, etc.; Others: autoimmune disorder, active tuberculosis, malignancies (e.g.tumor), neuropathic or metal illness history,etc.
6. Has used anti-HBV drug (Interferon, Lamivudine, Adefovir Dipivoxil, Entecavir and Telbivudine) and immunomodulator (Thymic peptide,etc ) 6 months prior to the administration of study medication
7. Has participated in any other drug clinical investigations within the past 3 months
8. Has allergy habitus or has suspected allergy to study drug
9. Female who is in pregnancy, in lactation or planning to become pregnant during the course of the study
10. Has a history of alcohol abuse (Alcohol consumption for more than 5 years, with daily consumption over 40g for males and over 20g for females) and known drug dependence
11. Has a history of organ transplant (except external corneal transplantation and hair transplantation)
12. Any other factors inappropriate for enrollment in the study or study completion in the view of the investigator
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Third Military Medical University
OTHER
Chongqing Jiachen Biotechnology Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lai Wei, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Hepatitis Institute of Peking University People's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The PLA Beijing Military General Hospital
Beijing, Beijing Municipality, China
The 2nd Affiliated Hosptial of Harbin Medical University
Harbin, Heilongjiang, China
Renmin Hosptial of Wuhan University
Wuhan, Hubei, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
Xiangya Hospital Central South University
Changsha, Hunan, China
81th Hospital of PLA
Nanjing, Jiangsu, China
Jilin University First Hospital
Changchun, Jilin, China
TangDu Hospital
XiAn, Shanxi, China
The First Affiliated Hospital of Xi'An JiaoTong University
Xi’an, Shanxi, China
West China Hospital,SiChuan University
Chengdu, Sichuan, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
302 Militray Hosptial of China
Beijing, , China
Hepatitis Institute of Peking University People's Hospital
Beijing, , China
Southwest Hospital
Chongqing, , China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wei L, Zhao T, Zhang J, Mao Q, Gong G, Sun Y, Chen Y, Wang M, Tan D, Gong Z, Li B, Niu J, Li S, Gong H, Zou L, Zhou W, Jia Z, Tang Y, Fei L, Hu Y, Shang X, Han J, Zhang B, Wu Y. Efficacy and safety of a nanoparticle therapeutic vaccine in patients with chronic hepatitis B: A randomized clinical trial. Hepatology. 2022 Jan;75(1):182-195. doi: 10.1002/hep.32109. Epub 2021 Dec 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
71006.01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.